IP Library Granted Patent US 12,129,249
Granted Patent B2
US 12,129,249 · App. 17/180,127 · Granted Oct 29, 2024

Method for producing optically active compound

Inventors: Sayuri Hirano (Osaka, JP); Yoshiyuki Takeda (Osaka, JP); Koji Nakamoto (Osaka, JP); Motoki Ikeuchi (Osaka, JP); Masato Kitayama (Osaka, JP); Masatoshi Yamada (Osaka, JP); Jun-ichi Kawakami (Osaka, JP)
Assignee: DAY ONE BIOPHARMACEUTICALS, INC.
C07D417/14C07D417/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,129,249
App. No.
17/180,127
Granted
Oct 29, 2024
Kind
B2
Abstract

The aim of the present invention is to provide a method capable of producing an optically active pyrimidinamide derivative on an industrial scale. Compound (I) or a salt thereof is subjected to an asymmetric reduction reaction, the obtained compound (II) or a salt thereof is subjected to a deprotection reaction, and the obtained compound (III) or a salt thereof is reacted with compound (VI) or a salt thereof to obtain compound (V) or a salt thereof. wherein each symbol is as defined in the specification.

Claims (22)

1. A method of producing an optically active form of a compound represented by the following formula (III):

wherein R 1 is a C 1-6 alkyl group;

R 2 is a hydrogen atom or a halogen atom;

R 3 is a hydrogen atom or an optionally halogenated C 1-6 alkyl group; and

the carbon atom marked with * is an asymmetric carbon atom, or a salt thereof,

wherein the method comprises subjecting a compound represented by the following formula (A-c):

wherein each symbol is as defined above, or a salt thereof,

to an asymmetric reductive amination reaction in the presence of an amine source, a reducing agent, and an organic metal complex.

2. The method of claim 1 , wherein the reducing agent is a hydrogen donor.

3. The method of claim 2 , wherein the hydrogen donor comprises hydrogen gas, a metal hydride, isopropyl alcohol, formic acid, benzthiazoline, or Hantzsch ester.

4. The method of claim 2 , wherein the hydrogen donor is hydrogen gas.

5. The method of claim 1 , wherein the amine source is an ammonium salt.

6. The method of claim 5 , wherein an acid used for forming the ammonium salt is selected from an optionally substituted salicylic acid, optionally substituted nicotinic acid, carbonic acid, formic acid, acetic acid, trifluoroacetic acid and benzoic acid.

7. The method of claim 5 , wherein the ammonium salt is ammonium salicylate.

8. The method of claim 1 , wherein the organic metal complex is selected from rhodium complexes, ruthenium complexes, iridium complexes, palladium complexes, nickel complexes, copper complexes, osmium complexes, platinum complexes, iron complexes, gold complexes, silver complexes, zinc complexes, titanium complexes, cobalt complexes, zirconium complexes, and samarium complexes.

9. The method of claim 8 , wherein the organic metal complex is an iridium complex.

10. The method of claim 1 , wherein the organic metal complex comprises a ligand.

11. The method of claim 10 , wherein the ligand is selected from 2,4-bis(diphenylphosphino)pentane (SKEWPHOS), SKEWPHOS derivative having 1 to 5 substituents on the benzene ring(s) bonded to the phosphorus atom of SKEWPHOS, 4,12-bis(diphenylphosphino)-[2,2]-paracyclophane(PhanePHOS), substituted-1,1′-bisphosphoranoferrocene (Ferrocelane), and 1-[2-(disubstituted-phosphino)ferrocenyl]ethyl-disubstituted-phosphine (Josiphos).

12. The method of claim 11 , wherein the ligand is SKEWPHOS.

13. The method of claim 1 , wherein the asymmetric reductive amination reaction is carried out in a solvent.

14. The method of claim 1 , wherein the asymmetric reductive amination reaction is carried out in the presence of a base, an acid, or a salt.

15. The method of claim 1 , wherein R 1 is methyl, R 2 is Cl, and R 3 is —CF 3 .

Assignments (4)
MERGER Recorded May 17, 2022
From: DOT THERAPEUTICS-2, INC.; DOT THERAPEUTICS-1, INC.
To: DAY ONE BIOPHARMACEUTICALS, INC.
Reel/Frame 059936/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: HIRANO, SAYURI; IKEUCHI, MOTOKI; KAWAKAMI, JUN-ICHI; KITAYAMA, MASATO; YAMADA, MASATOSHI; TAKEDA, YASHIYUKI; NAKAMOTO, KOJI
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055461/0318 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 055461/0511 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: MILLENNIUM PHARMACEUTICALS, INC.
To: DOT THERAPEUTICS-1, INC.
Reel/Frame 055461/0666 →
Priority Claims (1)
JP 2017-106280 · May 30, 2017 · national
Continuity (2)
Continuation 16617914
Related Publication 20210347769A1 · Nov 11, 2021